Evolus Cash Flow from Operating Activities 2016-2024 | EOLS
Evolus cash flow from operating activities from 2016 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
| Evolus Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $-18 |
| 2023 | $-34 |
| 2022 | $-85 |
| 2021 | $-33 |
| 2020 | $-58 |
| 2019 | $-93 |
| 2018 | $-26 |
| 2017 | $-13 |
| 2016 | $-13 |
| 2015 | $-36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.779B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||